Apeiron Biologics Ag Is A Biotechnology Company Based In Viennaaustriafocused On Developing And Commercializing Immunotherapies For Cancer And Respiratory Diseasesestablished As Austria S First Biotech Firmit Gained Recognition In 2017 With The Approval Of Qarzibaa Dinutuximab Beta A Monoclonal Antibody Therapy For High Risk Neuroblastoma In Childrenthis Product Is Available In Over 35 Countries And Is Licensed For Global Distribution To Recordati S P Awith Additional Rights In Mainland China Held By Beigeneltd The Company Is Actively Developing Therapies Targeting Solid Tumors And Hematological Malignancieswith Its Apn401 Program Currently In Clinical Developmentapeiron Has Also Spun Off An Immuno Oncology Pipeline Into Invios Holding Ag While Retaining Licensing Rights And A Robust Patent Portfoliowith A Small Team And A Revenue Of $7 8 Millionapeiron Combines Proprietary Drug Development With Strategic Partnerships To Enhance Its Global Presence In The Biopharmaceutical Industry
